Skip to main content
SpringerLink
Log in

Myocarditis after ICI therapy more common than first thought

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Based on data from 964 patients at Massachusetts General Hospital who received ICI therapy during the stated time period.

  2. LVEF = left ventricular ejection fraction

  3. CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1

References

  1. Mahmood SS, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology : [10 pages], 13 Mar 2018. Available from: URL: http://dx.doi.org/10.1016/j.jacc.2018.02.037.

  2. Tocchetti CG. Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. Journal of the American College of Cardiology : [3 pages], Apr 2018. Available from: URL: https://doi.org/10.1016/j.jacc.2018.02.038.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Myocarditis after ICI therapy more common than first thought. Reactions Weekly 1697, 9 (2018). https://doi.org/10.1007/s40278-018-44565-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44565-1

Search

Navigation